The goal of the Moffitt Cancer Center (MCC) Cancer Epidemiology (CE) Program is to contribute to a reduction in the cancer burden through research to identify risk factors across the cancer continuum comprising etiology, progression, and outcome, and the translation of that knowledge into successful prevention and early detection interventions. Rapid increases in information enabled by advances in technology have provided the opportunity to clarify underlying causes of cancer pathogenesis. The complexity of the collection of diseases known as cancer requires a robust approach and consideration for a broad array of biomarkers. The identification of markers that alter susceptibility to cancer allows for the development and testing of clinical cancer prevention strategies. To achieve its goal, the CE Program is organized into three specific aims focused on 1) identification and testing of acquired biomarkers of cancer risk and outcome, 2) examination of inherited susceptibility markers and associations with cancer risk and outcome, and 3) discovery and testing of promising approaches for the prevention and early detection of cancer. CE members investigate how biomarkers, some of which are modifiable, impact disease onset, progression, and outcome and whether these biomarkers can be brought forward into the clinical and public health realms for translational impact. Work is conducted in close collaboration with colleagues in the Health Outcomes and Behavior (HOB) Program, who seek to better understand behaviors that affect mutable biomarkers and modify those behaviors to decrease cancer risk and promote early detection. Thus, the specific aims of CE are highly complementary to those of HOB, and there is considerable synergy between members of both programs. The program comprises 24 members from six academic departments. Peer-reviewed funding is $6.7M in annual total costs, and the portion of this funding derived from NCI is $5.8M, representing 86% of the program's peer-reviewed funding. Program members have published 635 cancer-relevant scholarly articles including 58 in high impact journals (impact factor >10). In total, 174 (27%) of all publications represent intra- programmatic collaborations, 147 (23%) represent inter-programmatic collaborations, and 292 (46%) reflect inter-institutional collaborations with other NCI-designated Cancer Centers. Indeed, CE members currently have 37 inter-institutional collaborative awards. Scientific investigations led by program members have helped advance knowledge of risk factors, including methylation markers, human papilloma and other viruses, microRNA signatures, and genetic polymorphisms, for numerous cancers that are the major contributors to mortality and morbidity in the MCC catchment area, and for other cancers. CE Program members also are active in translating their work through developing better vaccines, botanical chemopreventive agents, and automated digital imaging to impact clinical and public health practice.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
H. Lee Moffitt Cancer Center & Research Institute
United States
Zip Code
Davis, Stacy N; Govindaraju, Swapamthi; Jackson, Brittany et al. (2018) Recruitment Techniques and Strategies in a Community-Based Colorectal Cancer Screening Study of Men and Women of African Ancestry. Nurs Res 67:212-221
Martínez, Úrsula; Brandon, Thomas H; Sutton, Steven K et al. (2018) Associations between the smoking-relatedness of a cancer type, cessation attitudes and beliefs, and future abstinence among recent quitters. Psychooncology 27:2104-2110
Perales-Puchalt, Alfredo; Perez-Sanz, Jairo; Payne, Kyle K et al. (2018) Frontline Science: Microbiota reconstitution restores intestinal integrity after cisplatin therapy. J Leukoc Biol 103:799-805
Nelson, Ashley M; Jim, Heather S L; Small, Brent J et al. (2018) Sleep disruption among cancer patients following autologous hematopoietic cell transplantation. Bone Marrow Transplant 53:307-314
Singh, Kshipra; Coburn, Lori A; Asim, Mohammad et al. (2018) Ornithine Decarboxylase in Macrophages Exacerbates Colitis and Promotes Colitis-Associated Colon Carcinogenesis by Impairing M1 Immune Responses. Cancer Res 78:4303-4315
Kasting, Monica L; Giuliano, Anna R; Reich, Richard R et al. (2018) Hepatitis C Virus Screening Trends: Serial Cross-Sectional Analysis of the National Health Interview Survey Population, 2013-2015. Cancer Epidemiol Biomarkers Prev 27:503-513
Denson, Aaron; Burke, Nancy; Wapinsky, Georgine et al. (2018) Clinical Outcomes of Patients With Gastrointestinal Malignancies Participating in Phase I Clinical Trials. Am J Clin Oncol 41:133-139
Betts, Brian C; Bastian, David; Iamsawat, Supinya et al. (2018) Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation. Proc Natl Acad Sci U S A 115:1582-1587
Pidala, Joseph; Beato, Francisca; Kim, Jongphil et al. (2018) In vivo IL-12/IL-23p40 neutralization blocks Th1/Th17 response after allogeneic hematopoietic cell transplantation. Haematologica 103:531-539
Hampras, S S; Tommasino, M; Zhao, Y et al. (2018) Cross-sectional associations between cutaneous viral infections and regulatory T lymphocytes in circulation. Br J Dermatol :

Showing the most recent 10 out of 1254 publications